Key result
Survivors of hematopoietic stem cell transplantation remain at risk for cardiovascular disease at a rate at least fourfold higher than the general population, warranting aggressive screening.
Answers are grounded in this paper and cite their sources.
HSCT survivors have a significantly elevated risk of cardiovascular complications, warranting aggressive screening and management of cardiac risk factors in collaboration with cardio-oncology.
OPINION STATEMENT: Survivors of hematopoietic stem cell transplant (HSCT) are at significant risk for cardiac disease and cardiac complications. While there may be cardiac complications during the acute period of HSCT, long-term survivors remain at risk for cardiovascular disease at a rate at least fourfold higher than the general population. Aggressive screening for cardiac risk factors such as diabetes, hypertension, and arrhythmias is warranted pretransplant. For those with risk factors, particularly a history of cardiovascular disease or atrial fibrillation, cardiology consultation is warranted in the pretransplantation period. Aggressive screening for cardiac risk factors such as diabetes, hypertension, and hyperlipidemia is warranted in HSCT survivors as well; early and aggressive treatment of left ventricular dysfunction is warranted. Collaboration between hematology/oncology and cardiology through a cardio-oncology clinic is an optimal way to help manage these patients.
No takes yet. Share an insight, caveat, or question.
Blaes et al. (2016) conducted a review in Hematopoietic Stem Cell Transplantation. Hematopoietic Stem Cell Transplantation was evaluated. Survivors of hematopoietic stem cell transplantation remain at risk for cardiovascular disease at a rate at least fourfold higher than the general population, warranting aggressive screening.
Synapse has enriched 10 related papers. Consider them for comparative context: